ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Granulomatosis with Polyangiitis (GPA)"

  • Abstract Number: 2380 • ACR Convergence 2023

    Renal Survival Rate of ANCA-associated Vasculitis in Korea: A Nationwide Population-Based Study Using Claims Data

    Chan-Bum Choi1, Jung-Min Shin2, Nayeon Choi3 and Soorack Ryu3, 1Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 2Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, South Korea, 3Biostatistical Consulting and Research Lab, Medical Research Collaborating Center, Hanyang University, Seoul, South Korea

    Background/Purpose: ANCA-associated vasculitis (AAV) is a rare systemic autoimmune disease with varying reports of incidence rates and clinical manifestations. Renal involvement is one of the…
  • Abstract Number: 0684 • ACR Convergence 2023

    Report on Twelve Patients with Diffuse Alveolar Hemorrhage in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis

    Ulrich Specks1, David Jayne2 and Peter Merkel3, 1Mayo Clinic, Rochester, MN, 2University of Cambridge, Cambridge, United Kingdom, 3University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Although respiratory tract involvement in ANCA-associated vasculitis (AAV) is frequent and associated with increased mortality, studies focusing on diffuse alveolar hemorrhage (DAH) in AAV…
  • Abstract Number: 2385 • ACR Convergence 2023

    Risk of Major Adverse Cardiovascular Events in ANCA-associated Vasculitis

    Jon Idoate1, Morgane Mourguet1, Thomas Villeneuve1, Grégoire Prevot1, Laurent Guilleminault2, Ribes David1, Stan Faguer1, Antoine Huart1, Dominique Chauveau1, Laurent Alric1, Martin Michaud1, Laurent Sailler1, Sébastien De Almeida Chavez1, Emmanuelle Mouchon1, Olivier Lairez1 and Gregory Pugnet3, 1CHU Toulouse, Toulouse, France, 2Department of respiratory and allergic diseases, Toulouse University Hospital Center, Toulouse, France, 3CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France

    Background/Purpose: The aim of this study was to investigate the risk of major adverse cardiovascular events (MACE) in patients with ANCA-associated vasculitis (AAV). Methods: We…
  • Abstract Number: 0442 • ACR Convergence 2022

    Induction Therapy Patterns for Severe ANCA-associated Vasculitis Differ Based on Physician Specialty, Expertise, and Practice Setting: An International Survey

    Lilian Xu1, Faten Aqeel1, Ojaswi Tomar2, Tingting Li2 and Duvuru Geetha1, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Washington University in St. Louis School of Medicine, St. Louis, MO

    Background/Purpose: Therapies for ANCA-associated vasculitis (AAV) have evolved over the last 3 decades. In light of new data on plasma exchange (PLEX) and glucocorticoid (GC)…
  • Abstract Number: 0453 • ACR Convergence 2022

    Validation of the 2022 – American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria in Patients with ANCA Associated Vasculitis

    Aman Sharma1, Prateek Deo1, Shankar Naidu2, Joydeep Samanta3, Sakshi Mittal3, Kusum Sharma3, Ritambhra Nada3, Varun Dhir4, sanjay jain2 and Ranjana Minz2, 1PGIMER, Chandigarh, India, Chandigarh, India, 2Postgraduate Institute of Medical Education and Research, Chandigarh, India, 3PGIMER, Chandigarh, India, 4PGIMER, CHD, INDIA, Chandigarh, India

    Background/Purpose: The purpose of this study was to validate the recently published 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for…
  • Abstract Number: 0454 • ACR Convergence 2022

    Advantages and Disadvantages in Applying 2022 ACR/EULAR Classification Criteria to Conventionally Diagnosed Japanese GPA Patients

    Ryo Kuwata1, Yuko Shirota2, Tsuyoshi Shirai3, Hiroyuki Yamashita1, Hiroko Sato3, Tomoki Takeda2, Yumiko Oka2, Takao Kodera4, Hiroshi Kaneko1, Junichi Kameoka5, Hiroshi Fujii3 and Tomonori Ishii6, 1Division of Rheumatic diseases, National Center for Global Health and Medicine, Tokyo, Japan, 2Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, 3Department of Rheumatology, Tohoku University Hospital, Sendai, Japan, 4Department of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, 5Divison of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, 6Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan

    Background/Purpose: The Chapel Hill Consensus Conference and the European Medicines Agency algorithm were commonly used to diagnose patients with granulomatosis with polyangiitis (GPA) 1). Recently…
  • Abstract Number: 0455 • ACR Convergence 2022

    Performance of 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria in Turkish Vasculitis Patients

    Ummugulsum Gazel1, Sevinc Can Sandikci2, Ahmet Omma3, Sinem Burcu Kocaer4, Fatoş Onen5, Onay Gercik6, Servet Akar7, Kerem Abacar8, Ebru Asicioglu9, Serhan Tuglular9, Fatma Alibaz-Oner8 and Haner Direskeneli10, 1University of Ottawa, Rheumatology, Ottawa, Canada, Ottawa, ON, Canada, 2Ankara Numune Education and Research Hospital, Rheumatology, Ankara, Turkey, 3Ankara Numune Education and Research Hospital, Rheumatology, Ankara, Turkey, Istanbul, Turkey, 4Dokuz Eylul University, Faculty of Medicine, Rheumatology, Izmir, Turkey, 5Dokuz Eylul University, Faculty of Medicine, Rheumatology, İzmir, Turkey, 6Izmir Tepecik Research Hospital, Izmir, Turkey, 7Izmir Katip Celebi University School of Medicine, Izmir, Turkey, 8Marmara University, Rheumatology, Istanbul, Turkey, 9Marmara University, Faculty of Medicine, Nephrology, Istanbul, Turkey, 10Marmara University, Rheumatology, Istanbul, Istanbul, Turkey

    Background/Purpose: The American College of Rheumatology (ACR)-1990 criteria is the most used method for the classification of ANCA Associated Vasculitis (AAV). However, with ACR-1990 criteria,…
  • Abstract Number: 0457 • ACR Convergence 2022

    A Systematic Literature Review Informing the 2022 Update of the EULAR Recommendations for the Management of ANCA-associated Vasculitis

    Jan Schirmer1, Beatriz Sanchez-Alamo2, Sara Monti3, Bernhard Hellmich4, David Jayne5 and Gunnar Tomasson6, 1University Medical Center Schleswig-Holstein, Kiel, Germany, 2Lund University, Skåne University Hospital, Lund, Sweden, 3Rheumatology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy, 4Medius Kliniken, University of Tübingen, Kirchheim Teck, Germany, 5University of Cambridge, Cambridge, United Kingdom, 6Centre for Rheumatology Research, University Hospital Reykjavik, Reykjavik, Iceland

    Background/Purpose: Since the publication of the 2016 European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of ANCA-associated vasculitis (AAV), the publication of…
  • Abstract Number: 0526 • ACR Convergence 2022

    Characteristics and Outcomes of Participants with and Without Diffuse Alveolar Hemorrhage in the Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis (PEXIVAS) Trial

    Lynn Fussner1, Luis Felipe Flores-Suarez2, Rodrigo Cartin-Ceba3, Ulrich Specks3, P. Gerard Cox4, David Jayne5, Peter Merkel6 and Michael Walsh4, 1The Ohio State University, Columbus, OH, 2Instituto Nacional de Enfermedades Respiratorias, Ciudad de México, Mexico, 3Mayo Clinic, Rochester, MN, 4McMaster University, Hamilton, ON, Canada, 5University of Cambridge, Cambridge, United Kingdom, 6University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Diffuse alveolar hemorrhage (DAH) is a potentially life-threatening manifestation of ANCA-associated vasculitis (AAV). Studies describing patients with DAH in AAV have typically been small…
  • Abstract Number: 0527 • ACR Convergence 2022

    Rituximab as Maintenance Therapy for ANCA-associated Vasculitides: Pooled Analysis and Long-term Outcome of MAINRITSAN Trials

    Florence Delestre1, Pierre Charles2, Loïc Guillevin3, Raphaël Porcher4 and Benjamin Terrier3, 1cochin Hospital, Paris, France, 2Institut Mutualiste Montsouris, Paris, France, 3National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, 4Université Paris Cité, Hôtel-Dieu, Paris, France

    Background/Purpose: Maintenance therapy after induction of remission has been shown to reduce relapse rate and mortality in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. The three MAINRITSAN…
  • Abstract Number: 0528 • ACR Convergence 2022

    Nasal Epithelial Gene Expression Profiling Preceding Relapse in Patients with Granulomatosis with Polyangiitis

    Fang R. Zhao1, Rebecca Deek2, James Garifallou3, Jalal Jalaly2, Cailu Lin4, Danielle Reed4, Shubhasree Banerjee2, Naomi Amudala2, Antoine Sreih5, Sherry Chou2, Virginia Livolsi2, Ronald Collman2, Hongzhe Lee2, Peter Merkel2, Peter Grayson6, Noam Cohen2, Jonathan Miner2 and Rennie Rhee2, 1Washington University in St. Louis, St. Louis, MO, 2University of Pennsylvania, Philadelphia, PA, 3Children's Hospital of Philadelphia, Philadelphia, PA, 4Monell Center, Philadelphia, PA, 5Bristol Myers Squibb, Philadelphia, PA, 6National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD

    Background/Purpose: Predicting relapse is a major challenge in granulomatosis with polyangiitis (GPA). We previously demonstrated changes in the nasal microbiota, particularly Corynebacterium tuberculostearicum, prior to…
  • Abstract Number: 1071 • ACR Convergence 2022

    Trimethoprim Sulfamethoxazole Use in Patients with Granulomatosis with Polyangiitis Treated with Rituximab

    Arielle Mendel1, Hassan Behlouli2, Cristiano Moura2, Evelyne Vinet1, Jeffrey Curtis3 and Sasha Bernatsky2, 1McGill University Health Centre, Montréal, QC, Canada, 2Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 3Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Trimethoprim sulfamethoxazole (TMP-SMX) prophylaxis is recommended during induction of ANCA-associated vasculitis (AAV) to prevent pneumocystis jirovecii pneumonia (PJP), and may also reduce the risk…
  • Abstract Number: 1072 • ACR Convergence 2022

    Efficacy and Safety Assessment of a Rituximab Biosimilar in Patients with Granulomatosis with Polyangiitis (GPA)

    Adil Vural1, Komal Mushtaq1, Chao Zhang1, Mahmoud Alwakeel1, Vickie Sayles1, Kristine Duly2, Carol Langford1 and Rula Hajj-Ali3, 1Cleveland Clinic, Cleveland, OH, 2Cleveland Clinic, Fairview Park, OH, 3Cleveland Clinic, Hunting Valley, OH

    Background/Purpose: A biosimilar is a medication that is highly similar to a biologic agent that is already approved by a regulatory organization. Considering the share…
  • Abstract Number: 1080 • ACR Convergence 2022

    Performance of Risk Prediction Models for Relapse and Severe Infection at the End of 18-month Rituximab Maintenance Therapy in ANCA-associated Vasculitides: Data from the MAINRITSAN Trials

    Florence Delestre1, Pierre Charles2, Loïc Guillevin3, Raphaël Porcher4 and Benjamin Terrier3, 1cochin Hospital, Paris, France, 2Institut Mutualiste Montsouris, Paris, France, 3National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, 4Université Paris Cité, Hôtel-Dieu, Paris, France

    Background/Purpose: Long-term follow-up analysis of the three MAINRITSAN trials confirmed the efficacy of rituximab (RTX) in preventing relapses in ANCA-associated vasculitis (AAV), especially RTX administration…
  • Abstract Number: 1082 • ACR Convergence 2022

    Outcomes of Methotrexate as an Initial Induction and Maintenance Regimen for Localized Granulomatosis with Polyangiitis: A Retrospective Review

    Pratyusha Banik1, Marcia Friedman2, Daniela Ghetie3, Dongseok Choi4 and Margaret Brophy1, 1Oregon Health & Science University, Portland, OR, 2Oregon Health and Science University, Division of Arthritis and Rheumatic Diseases, Portland, OR, 3Oregon Health & Science University, Division of Arthritis and Rheumatic Diseases, Lake Oswego, OR, 4OHSU-PSU School of Public Health, Portland, OR

    Background/Purpose: While there is established data regarding the induction and maintenance treatment of systemic or organ threatening granulomatosis with polyangiitis (GPA), there is limited data…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology